Key result
ACE I/D genetic polymorphism was not associated with risks for polycystic ovary syndrome, though the II genotype subgroup had a higher level of total oxidant status than the DD genotype (P<0.05).
Why the study?
To investigate the relationship between the ACE I/D gene polymorphism and genetic risks for PCOS, and evaluate its impact on clinical, hormonal, metabolic, and oxidative stress parameters.
Is ACE I/D gene polymorphism associated with the risk of polycystic ovary syndrome and its clinical, hormonal, metabolic, and oxidative stress parameters?
Case-Control (n=1,845)
No
Is ACE I/D gene polymorphism associated with the risk of polycystic ovary syndrome and its clinical, hormonal, metabolic, and oxidative stress parameters?
ACE I/D gene polymorphism does not increase the risk of PCOS but may influence metabolic and oxidative stress parameters in affected patients.
OBJECTIVE: To investigate the relationship between angiotensin Ⅰ-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and the genetic risks for polycystic ovary syndrome (PCOS) and to evaluate the impact of ACE I/D genotypes on clinical, hormonal, metabolic and oxidative stress parameters in patients with PCOS. METHODS: This was a retrospective case-control study involving a total of 1 020 PCOS patients and 825 female controls who visited the outpatient clinic of the Department of Reproductive Endocrinology, West China Second Hospital of Sichuan University between 2006 and 2019. The ages of the subjects ranged between 17 and 44. The ACE I/D genotypes were determined by polymerase chain reaction (PCR) and gel electrophoresis. 667 PCOS patients and 527 controls were selected for an analysis of their genotypes and the hormonal, metabolic and oxidative stress parameters. RESULTS: <0.05). In the control group, II genotype subgroup had a higher level of total oxidant status (TOS) than that of the DD genotype subgroup. CONCLUSION: I/D genetic polymorphism is not associated with risks for PCOS. The I/D variation of ACE gene may be related to insulin resistance, dyslipidaemia, hyperandrogenemia and oxidative stress in PCOS patients.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2021) conducted a case-control in Polycystic ovary syndrome (PCOS) (n=1,845). ACE I/D gene polymorphism vs. Controls (without PCOS) was evaluated on Risk for polycystic ovary syndrome. ACE I/D genetic polymorphism was not associated with risks for polycystic ovary syndrome, though the II genotype subgroup had a higher level of total oxidant status than the DD genotype (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: